

# Nonclinical development of AR degrader UBX-103335 for the treatment of metastatic castration-resistant prostate cancer

Ubix Therapeutics



ONCOLOGY	Preclinical
Product Type	Small molecule targeted protein degrader
Indication	Metastatic castration-resistant prostate cancer (mCRPC)
Target	Androgen receptor (AR)
MoA(Mechanism of Action)	Targeted Degradation of AR
Competitiveness	<ul style="list-style-type: none"> <li>• <b>Medical unmet needs</b> <ul style="list-style-type: none"> <li>- Most prostate cancer patients acquire resistance to current therapies such as ADT and AR signaling inhibitors and develop into mCRPC, a leading cause of death.</li> <li>- Resistance to AR signaling inhibitors is mainly attributed to AR amplification and AR point mutations. AR degradation represents a promising alternative that can overcome the drug resistance mechanisms.</li> </ul> </li> <li>• <b>Key points of differentiation</b> <ul style="list-style-type: none"> <li>- Highly potent, selective, and orally available AR degrader</li> <li>- Effectively address clinically relevant AR point mutations.</li> <li>- Exhibits PK/PD profiles that is more favorable to competing programs.</li> <li>- Exhibits anti-tumoral activity superior to competing programs in intact, castrated, and enzalutamide-resistant VCaP xenograft models.</li> </ul> </li> </ul>
Development Stage	Preclinical(IND-enabling studies)
Dosage Route	Oral administration